Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2022.02.13.22270898: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: Thank you for sharing your code.


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Statement of principal findings: We have shown that: Strengths and limitations: Strengths of this study are the complete ascertainment of cases, the comprehensive linkage to electronic health records, and the incidence density sampling design that controls for calendar time, age, sex and general practice. A limitation is that the data on prescribin of biologics is only a snapshot of those on biologics in March 2020, and it covers only about one-third of the Scottish population. Hospital outpatient prescribing is not recorded in electronic form within the NHS, and the prescription records held by the medication homecare services companies were not available for this study. Although the clinics that provided ths biologics list are not representative of the Scottish population, the matching of cases and controls on general practice ensures that the controls are drawn from the catchment population of these clinics. However because the coverage of the list is limited, the sample size is not large enough to estimate reliably the effects of specific classes of biologics such as B cell depleters, or the efficacy of vaccines in those on biologics. Comparison with other studies: The rate ratio of 2.1 for hospitalised COVID-19 in rheumatology patients treated with csDMARDs is rather higher than the rate ratio of 1.3 for mortality associated with any diagnosis of rheumatoid arthritis, lupus or psoriasis (not restricted to those with arthritis) in the OpenSAFELY study [11]. The rate ratio...

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.